▪ Reaching the milestone of 20 locations in the EFICAS study
▪ Intermediate results of the study higher than expected
▪ Confirmation of short-term financial support from several key shareholders
Paris, May 6, 2024 – 7:00 a.m. CEST
CARMAT (FR0010907956, ALCAR, PEA-PME eligible), designer and developer of the most advanced total artificial heart in the world (the “Company” or “CARMAT”), aiming to offer a therapeutic alternative to patients suffering from advanced biventricular heart failure , today provides an update on the EFICAS study and reiterates its confidence in its 2024 prospects.
To receive all CARMAT financial information in real time, request it by email to [email protected]. Your registration will be immediate.